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Abstract (200 max) 
Purpose: We have evaluated deficiencies in existing diagnostic criteria for neurofibromatosis 
2 (NF2).  
Methods: Two large databases of individuals fulfilling NF2 criteria (n=1361) and those 
tested for NF2 variants with criteria short of diagnosis (n=1416) were interrogated.  
We assessed the proportions meeting each diagnostic criterion with constitutional or 
mosaic NF2 variants and the specificity with regard to refuted diagnosis. 
Results: There was no evidence for usefulness of old criteria ‘glioma’ or ‘neurofibroma’. 
‘Ependymoma’ had 100% specificity and high levels of confirmed NF2 diagnosis 
(67.7%). Those with bilateral vestibular schwannoma (VS) alone aged ≥60 years had 
the lowest confirmation rate (6.6%) and reduced specificity (80%). Siblings as a first-
degree-relative, without an affected parent, had 0% specificity. All three individuals 
with a unilateral VS and an affected sibling were proven not to have NF2. The biggest 
overlap was with LZTR1-associated schwannomatosis. In this category, seven 
individuals with a unilateral VS plus ≥2 non-dermal schwannomas reduced specificity 
to 67%. 
Conclusion: The present study has confirmed important deficiencies in NF2 diagnostic 
criteria. The term ‘glioma’ should be dropped and replaced by ‘ependymoma’. 
Similarly ‘neurofibroma’ should be removed. Dropping ‘sibling’ from first-degree-
relatives should be considered and testing of LZTR1 should be recommended for 
unilateral VS. 
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INTRODUCTION (words 3904 max 4000) 
The two main sets of diagnostic criteria for neurofibromatosis 2 (NF2) date back to 1987 1 
and 1992, 2 although a points based system was devised in 2011 3. The Manchester criteria 
devised in 1992 2 still appear to be the most widely used and were shown to be superior to the 
original criteria in 2002 4. Deficiencies were still noted, in that individuals with de novo NF2 
often had a prolonged period with signs attributable to the disease, but without meeting 
diagnostic criteria 4. More recently a number of the individual criteria have received more 
scrutiny. The term ‘glioma’ in the original sets of criteria has increasingly been seen as an 
incorrect descriptor. There is no convincing evidence that high grade glioma is part of NF2 5, 
with the great majority of intrinsic NF2 associated spinal cord lesions being histologically 
proven to be ependymomas 6, and low grade gliomas being relatively uncommon 5. The 
discovery of the involvement of the LZTR1 gene in the development of schwannomas in 2014 
7 led to the identification of substantial diagnostic overlap between schwannomatosis and 
NF2 in particular in those with a unilateral vestibular schwannoma (VS) and multiple other 
non-dermal schwannomas 8,9. A proposed update to the Manchester NF2 criteria was made to 
particularly address the overlap with schwannomatosis (table 1) 9. Even the hallmark of NF2, 
bilateral vestibular schwannoma, has recently been shown to occur by chance, unrelated to a 
common NF2 pathogenic variant. Indeed, calculations showed that in almost 50% of those 
with symptomatic bilateral tumours alone over the age of 70, co-occurrence may have 
happened by chance 10. These deficiencies prompted us to re-examine the criteria using two 
large clinical and molecular databases in the UK. 
 
METHODS 
Two clinical databases curated since 1994 were utilised. A database of 1460 patients (1210-
83% from the UK) meeting existing NF2 diagnostic criteria, or harbouring a constitutional 
pathogenic variant in NF2, or a mosaic pathogenic variant classified as occurring at lower 
than 50% allele frequency or identified as common between two anatomically distinct NF2 
related tumours. A second database containing 1416 individuals who had undergone 
molecular analysis with one or more NF2 diagnostic criterion without fulfilling full NF2 
criteria was also interrogated. 
Each main diagnostic feature was taken as a major criterion. Thus bilateral vestibular 
schwannoma, unilateral vestibular schwannoma, multiple meningiomas and an affected first 
degree relative with NF2 were taken as the ‘major’ criteria leading to diagnosis. Whichever 
of the major criteria was met first, ensuring a confirmed diagnosis (if required with sufficient 
minor criteria), was taken as the main route to diagnosis. If for instance an individual 
presented with a unilateral vestibular schwannoma (VS) aged 25 years and a single 
meningioma aged 27 years before developing a contralateral VS aged 30 years, they only met 
diagnostic criteria at 30 years by virtue of bilateral VS. If, however, two meningiomas were 
present aged 27 years, the unilateral VS plus 2 items from another category would have 
fulfilled diagnostic NF2 criteria at age 27 years. If the diagnosis was made based on unilateral 
VS plus 2+ meningiomas they were included in the Unilateral VS plus 2 other category rather 
than in the 2+ meningiomas + unilateral VS category.  
Separate analysis was carried out on those who had an ependymoma without bilateral VS at 
diagnosis and on all those who met the 2+ meningioma category without bilateral VS at 
diagnosis (to include the unilateral VS criterion). Finally late onset (age ≥60 years) of 
bilateral VS alone was assessed separately. 
Molecular analysis 
All individuals underwent lymphocyte DNA analysis for NF2, with additional analysis in 
LZTR1 and SMARCB1 in cases meeting the unilateral VS category as well as those with 
multiple schwannomas. NF2 pathogenic variant testing of lymphocyte DNA (and tumour 
when available) used sequencing of all exons and intron exon boundaries and multiple 
ligation-dependant probe amplification (MLPA). In addition loss of heterozygosity was 
assessed with intragenic polymorphic markers as well as flanking markers on tumour 
specimens. Similar analysis was performed for LZTR1 and SMARCB1. Since 2013, all 
clinical genetic testing has been by next generation sequencing (NGS). Individuals with de 
novo NF2 and learning problems also had chromosome analysis for ring 22 and those with 
unfound familial NF2 were tested for translocations. Mosaicism was defined as definite 
when: 1. A pathogenic variant was detectable in blood (often only after NGS guided by 
tumour analysis) or 2. An identical pathogenic variant was found in two anatomically distinct 
tumours. A third category of ‘probable’ mosaicism was when an individual, fulfilling NF2 
diagnostic criteria, but with only one tumour available for analysis, had both mutational 
events found in a single tumour only. An NF2 diagnosis was refuted when molecular events 
were not consistent between two tumours or when NF2 testing did not identify a 
constitutional or mosaic variant and/or a pathogenic variant was found in another gene (e.g. 
LZTR1). 
Specificity was calculated for those with either definite confirmed or refuted NF2. Apart from 
identification of an LZTR1 pathogenic variant in the absence of a germline NF2 variant the 
absence of a common genetic variant in two NF2 tumours was considered evidence of 
exclusion of NF2. 
 
RESULTS 
In total there were 1029 de novo individuals (three without an affected parent but with a 
sibling with NF2), and 332 with an affected parent that had sufficient information to assess 
diagnostic category. The 1029 de novo cases were diagnosed at a median age of 34 years 
(range 0.5-86) whereas the inherited cases were diagnosed at a median age of 22 years (range 
0.2-82). The summary data of molecular analysis in those meeting existing criteria are 
presented in table 2. The population was divided into de novo cases or those without an 
affected parent and those with an affected parent. Median age at diagnosis in each molecular 
category: constitutional pathogenic variant, mosaic/presumed mosaic variant, and no 
pathogenic variant found, is presented for de novo cases in table 3. 
 
De novo or with unaffected parent 
There were high levels of specificity for a definite confirmed diagnosis in all diagnostic 
categories (last column table 2) except for individuals with a unilateral VS plus a sibling with 
NF2 and individuals with a unilateral VS plus two or more schwannomas. However, across 
all categories, there were low levels of NF2 confirmation (19.6-31.9%) in those initially 
presenting with a unilateral VS. This is a particular concern in the unilateral VS plus ≥2 
schwannomas category where only 27.6% had a definite NF2 diagnosis and 7 cases were 
ultimately found to have a pathogenic LZTR1 variant. Of four cases without an NF2 or 
LZTR1 variant identifiable in blood, but for whom two tumours were available for analysis, 
three carried an identical NF2 variant in both tumours, while one did not have an NF2 
variant, or an LZTR1 or SMARCB1 variant in common in both tumours. This excludes NF2 as 
the diagnosis in this last case and, along with the LZTR1 cases, means that, of those who had 
been given a definite diagnosis on clinical grounds, 8/24 (33%) did not have NF2. All NF2 
negative cases had LZTR1 and SMARCB1 analysis. This case with refuted NF2 had received 
brain and mantle radiotherapy for lymphoreticular malignancy in late teenage (case 157731-
table 4) and subsequently developed a unilateral VS aged 40 with a C8 spinal lesion and 
axillary schwannoma. He subsequently developed a Malignant Peripheral Nerve Sheath 
Tumour (MPNST) aged 51 in the C8 lesion, and thyroid cancer. Neither the C8 nor axillary 
lesion had an identifiable NF2 variant, nor chromosomal loss, ruling out the c.1574+1G>A 
variant found in the VS as the causative variant. Five further cases with childhood 
radiotherapy are shown in table 4. Case 9116 was identified as having a c.241-9A>G splicing 
variant confirmed after fractionated radiotherapy for bilateral optic pathway meningioma. 
Bilateral VS were identified 2 years later. The remainder all had NF2 tumours 12-25 years 
later consistent with radiation induced tumours. 
The lowest detection rate was found in individuals with bilateral VS diagnosed aged ≥60 
years. Overall, only four of 61 (6.6%) had a full constitutional pathogenic variant (c.600-
447_600-445delins8; c.19delT, p.(Ser7ProfsTer3); c.15delC, p.(Ile5MetfsTer5); 
c.1737+3A>T). There was no confirmed case of mosaicism in this category. Although three 
individuals in this category had two pathogenic variants identified in a single tumour, neither 
was detectable in lymphocyte DNA. In a fourth case, two tumours were analysed and 
different unrelated NF2 pathogenic variants were identified in each tumour, excluding a 
diagnosis of NF2 10. 
The median age at onset was significantly lower for each main diagnostic category in 
individuals with an identified constitutional NF2 variant versus those with no variant 
identified, while mosaic cases were usually intermediate. 
UVS in sibling or parent of NF2 case 
Two cases of individuals with unilateral VS were diagnosed after having a child diagnosed 
with NF2. Low level NF2 mosaicism (allele frequency 10%), was diagnosed in one parent 
after a daughter was diagnosed with bilateral VS. A second parent had been diagnosed with a 
unilateral VS aged 22 and was only diagnosed with NF2 after his child developed bilateral 
VS in childhood. Cutaneous examination revealed likely schwannomas but DNA 
confirmation was never undertaken. Three unrelated individuals with a unilateral VS and a 
sibling with NF2 (parents unaffected) did not carry the pathogenic variant identified in their 
sibling. The VS were diagnosed aged 29, 39 and 49 years. Full NF2, LZTR1 and SMARCB1 
variant analysis also proved negative in lymphocyte DNA. For the 29 year old the variant 
identified in her tumour was not seen in lymphocyte DNA. There were no situations in 1361 
NF2 cases in which an individual with a unilateral VS, an affected sibling and unaffected 
parents would have been diagnosed with NF2. 
 
Multiple meningiomas as a criterion 
Although a single meningioma is in the ‘other’ category, 2+ meningiomas can count as a 
‘major’ criterion. When analysing 2+ meningiomas separately in all the categories including 
unilateral VS + 2 meningiomas the detection rates were higher and more specific than the 
Unilateral VS category. Overall, 52/137 (38%) with 2 or more meningiomas, had confirmed 
NF2 with none where the diagnosis was refuted, compared to only 45/207 (21.7%) with a 
unilateral VS as major criterion (p=0.001). In particular, there were 32 individuals with 2+ 
meningiomas in whom the NF2 diagnosis was made with two additional NF2 features, but no 
VS, and 17/32 (53%) had molecularly confirmed NF2. This was particularly useful in 
childhood with 11/12 of those diagnosed aged <15 years having a full constitutional 
pathogenic variant. There were 4 mosaic cases. A 60 year old with 7 meningiomas and 4 
spinal schwannomas had a 4% allele frequency of the c.169C>T p.(Arg57Ter) variant. Three 
further cases aged 47, 48 and 51 had an identical pathogenic variant found in two 
anatomically distinct meningiomas. 
There were 5 unrelated parents with an affected child with NF2 and bilateral VS who had 
died with multiple meningiomas and no known VS. Unfortunately, no material was available 
to confirm the proven constitutional pathogenic variant in the child in these cases. A sixth 
parent with 6 meningiomas (died aged 68 years) who had a deceased child with NF2, had no 
pathogenic variant identified in blood and no material was available from the daughter. Four 
of the six parents were males. 
None of the SMARCB1 variant positive patients in the second Manchester database met NF2 
criteria with 2 or more meningiomas (3/70 had a single meningioma). Fifty individuals with 
multiple meningiomas have been tested, including 20 who meet NF2 criteria, and no 
SMARCB1 variant has been found. Eight unrelated individuals with multiple meningiomas, 
but no other features of NF2, had germline pathogenic variants in SMARCE1 11,12. All of 
these individuals had clear cell meningiomas, rather than the fibroblastic or transitional 
meningiomas, which are more common in NF2. 
Intrinsic brain and spinal cord tumours 
The great majority of intrinsic tumours in NF2 were presumed ependymomas with very few 
undergoing resection. Of those intrinsic tumours with pathological confirmation, four were 
low grade gliomas and only one was a high grade glioma occurring after previous irradiation 
5. None of these tumours would have aided an earlier diagnosis of NF2. There were 157 
(12%) confirmed (n=10) or presumed (n=147) spinal cord ependymomas. The presence of an 
ependymoma increased the likelihood of identifying a pathogenic variant in those without 
bilateral VS to 68% (21/31), which was significantly higher than all other categories 
(p<0.0001). The addition of ependymoma to the criteria would have advanced diagnosis by 
1-23 years in 18 individuals who would not otherwise have met criteria. In 3 cases, an 
apparently sporadic ependymoma aged 13, 14 and 24 years would have led to an even earlier 
diagnosis by 2-4 years if genetic analysis of NF2 was initiated at time of ependymoma 
diagnosis. 
Ocular features 
The database did not hold extensive ocular features on NF2 patients. Nonetheless, 
undertaking molecular analysis on children with visual symptoms revealing retinal 
hamartoma or epiretinal membranes would have led to an earlier diagnosis before VS were 
diagnosed in at least 15 de novo affected children. In one child, the presence of amblyopia 
and epiretinal membranes led to mutational analysis that identified a pathogenic NF2 variant 
when the child was one year old (Table 2). 
Neurofibroma 
At least 67 (5%) NF2 patients had a pathology report stating ‘neurofibroma’. The great 
majority of these, that had undergone secondary pathology review, were reclassified as 
schwannoma. Even assessing those without pathology review, none would have led to an 
earlier diagnosis of NF2 using existing criteria. 
Offspring of NF2 affected individuals 
There were no particular issues identified to suggest deficiencies in the diagnostic criteria in 
this category, although a single case of unilateral VS aged 52 years in the daughter of a late 
onset case with bilateral VS aged 75 years may reflect an inaccurate diagnosis. No 
pathogenic variant was identified in either the woman or her mother. Overall, detection rates 
were all >95% in keeping with overall detection rates for familial NF2. 
 
DISCUSSION 
The present study has confirmed a number of deficiencies with the 1987 National Institutes of 
Health and 1 1992 Manchester criteria 2. Perhaps the most pressing need for a change in the 
criteria is from the term ‘glioma’ to ‘ependymoma’. It is clear that the radiological and 
pathological features of the predominant CNS intrinsic tumour seen in NF2 is a spinal cord 
ependymoma 5,6. These have generally been treated conservatively as they are indolent in the 
great majority of cases, but timely surgery clearly has a place in those with tumours over 
15mm in length 13. Ependymoma is clearly a very useful tumour in classifying NF2 in those 
with a unilateral VS 9 or multiple meningiomas. The high pathogenic variant detection rate of 
68% is the highest of all the de novo categories. 
 
The main diagnostic overlap is with schwannomatosis. In this report, we document two 
further de novo cases with a unilateral VS and two or more non-dermal schwannomas 
(without other NF2 features), who harbour LZTR1 pathogenic variants, bringing the total 
number to seven 9. This means that of those with a clinically confirmed diagnosis, only 67% 
have NF2, and the majority of these are mosaic. It is likely that the great remainder of those 
in this category without confirmed diagnosis have NF2 as they do not have an LZTR1 variant 
in blood or tumour. However, at least one further case without a SMARCB1 or LZTR1 variant 
had two tumours with divergent NF2 variants, excluding NF2 and potentially confirming a 
missed LZTR1 variant or another chromosome 22 schwannomatosis gene. It should be 
mandatory to undertake molecular analysis to confirm whether individuals with unilateral VS 
and other schwannomas have NF2 or LZTR1-related schwannomatosis, as the consequences 
of these two disorders and differences in transmission risk will be substantial, particularly as 
those with NF2 variants only detectable in tumour will have a very low transmission risk to 
children 14. Similarly, those with multiple non-vestibular schwannomas, without other NF2 
features, may well have mosaic NF2. In the current report, three of 13 cases in this category 
have developed a VS and 10 further cases have not 15. About 50% of apparent 
schwannomatosis cases who do not have an LZTR1 or SMARCB1 variant have mosaic NF2 
15. 
 
The present report also confirms that the presence of multiple meningiomas is as useful, or 
better than, a unilateral VS as a ‘major’ criterion. The NF2 pathogenic variant detection rate 
is significantly higher in de novo cases meeting criteria without bilateral VS in those with two 
or more meningiomas than in those with a unilateral VS. A number of parents of NF2 cases 
had multiple meningiomas and it is likely that these were mosaic for the pathogenic NF2 
variant (the fact that 4/6 were male is unusual). Multiple meningiomas account for only 5% 
of patients with meningioma and at least 20% of these have NF2 16. The population lifetime 
risk for multiple meningioma without NF2 is likely to be no more than 1 in 10-20,000 16 and 
so a chance association with NF2 appears less likely than a unilateral VS, which occurs in 1 
in 1000 people in their lifetime 10. The main diagnostic overlap concern for multiple 
meningiomas would be with SMARCB1-associated schwannomatosis. Although we have not 
found SMARCB1 pathogenic variants in any case with more than one meningioma, 
occasional families with multiple meningioma and a SMARCB1 pathogenic variant have been 
described 17. 
 
The present report also calls into question the use of a ‘sibling’ with an unaffected parent as a 
diagnostic criterion. There are only two reported instances in the literature of siblings affected 
with NF2 and no affected parent 18,19. In neither of these cases did one present with a 
unilateral VS only. The likelihood of a sibling presenting only with a unilateral VS is small as 
only around 5% of de novo NF2 patients present with an apparently sporadic unilateral VS 20. 
Nearly all of these are mosaic for the pathogenic variant 20 whereas a sibling would have a 
full constitutional change. This scenario also depends on the parent only having confined 
gonadal mosaicism which appears extremely rare in NF2 as nearly all cases of parental 
mosaicism involve at least some level of detection in other tissues 14. All three cases in the 
present report who have a unilateral VS and an NF2 affected sibling had not inherited the 
pathogenic variant identified in the sibling. Thus, the term first degree relative in the 
diagnostic criteria should probably exclude siblings with clearly unaffected parents, although 
molecular testing should clarify the situation in most instances. 
Ophthalmic features consistent with NF2 in childhood should prompt molecular analysis 21,22. 
A number of children could have had an earlier diagnosis with timely genetic assessment. 
Retinal hamartoma and childhood epiretinal membranes should be considered as potential 
‘minor’ criteria for NF2 in addition to juvenile subcapsular and cortical cataracts 21-23. 
The nerve sheath tumour ‘neurofibroma’ is what has given neurofibromatosis its name. 
However, true pathological neurofibromas are rare in NF2 24. Nonetheless, about 26% of 
nerve sheath tumours in NF2 have ‘features’ of schwannoma and neurofibroma and are more 
correctly designated as ‘hybrid’ tumours 24. It is likely that until this pathological term 
becomes universal that NF2 patients will continue to get an ‘inaccurate’ diagnosis of 
neurofibroma. Such a diagnosis in a patient with NF2 features should prompt secondary 
pathology review. The continued use of ‘neurofibroma’ within the NF2 criteria is highly 
questionable. 
 
The final criterion that needs addressing is the hallmark of NF2 itself, bilateral VS. Both of 
the early criteria 1,2 make bilateral VS sufficient for diagnosis although the points system 
from 2011 includes an age cut off of 30 years such that bilateral VS >30 years alone did not 
meet criteria for definite NF2. We have previously calculated that 1 in 2 million people will 
develop bilateral VS by chance 10 and that close to 50% of those with symptomatic bilateral 
VS ≥70 would be due to chance alone. In reality, with increasing use of magnetic resonance 
imaging, many people with bilateral VS identified in older life are not even symptomatic on 
one side. The very low detection rate for pathogenic variants of 6.6% (4/61)  in isolated 
bilateral VS aged ≥60 is highly significantly less than in other diagnostic categories: 52/137 
(38%) for 2+ meningiomas (p<0.0001) and 45/209 (21.5%) p=0.0075 for unilateral VS plus 
two other. Nonetheless, the four identified with pathogenic variants had hypomorphic de 
novo variants (two exon 1 frameshift variants and two splicing variants) that would still have 
important implications to children 25. If an age limit for definite NF2 were introduced for 
bilateral VS it would be vital that offspring risks were still addressed.  
 A final consideration is that schwannomas and meningiomas are radiation inducible tumours, 
especially with therapeutic radiation in childhood 26. In one study, amongst 3013 patients 
treated with radiotherapy before the age of 16, mostly for enlarged tonsils 27, seventy (2.3%) 
of the patients developed neural tumours, with seven developing multiple schwannomas or 
meningiomas. This is far higher than the birth incidence of NF2 and schwannomatosis 
combined 15. More recently, three of 33 sporadic adults meeting NF2 criteria in Israel had 
received cranial radiotherapy in childhood and none had an identifiable NF2 variant on blood 
analysis 28. We have presented five further cases with childhood radiotherapy who also had 
no NF2 variant on blood analysis. In one of these cases the diagnosis of NF2 could be 
refuted. As such, individuals who meet NF2 criteria only due to tumours arising >8 years post 
radiotherapy in childhood, it should be considered that their tumour are more likely to be 
caused by radiation than NF2 29. 
 
The current study has some limitations. In an ideal situation, to evaluate the true specificity of 
each criterion, two tumours from all those without confirmed NF2 should be analysed. In 
those with late onset bilateral VS it is extremely rare for more than one to be removed and a 
high proportion of those that are treated receive radiation therapy. In the 30 patients without 
LZTR1 variants that had two tumours analysed, three (10%) refuted the diagnosis of NF2. As 
such, the specificity values reported in this paper are likely to be overestimates, particularly 
in the categories with a low overall NF2 detection rate. Nonetheless, the present study 
represents by far the largest assessment of diagnostic criteria based on close to 3000 patients 
with molecular analysis. It includes potentially all of the identified NF2 cases in England 
through the four designated highly specialised commissioned centres 15 and includes referrals 
for molecular testing of all those with a >1% chance of harbouring an NF2 pathogenic variant 
in the last 8 years 19. Although the molecular confirmation of NF2 appears very low, this is 
most likely to be attributable to mosaicism, as most evaluable cases (90%) with two tumours 
had an identical NF2 variant detected in each tumour. The overall detection rate of 95% 
(sensitivity) for the second generation is reflected in table 2 and our previous research 15. We 
did not evaluate ‘cerebral calcification’ as the use of CT scans has been limited since 1992. 
As we would not recommend use of CT solely to identify if calcification were present 
particularly in childhood we would not recommend this criterion is retained due to concerns 
about specificity. 
 
In conclusion, the present report has identified a number of clear deficiencies in the current 
diagnostic criteria for NF2. There is a pressing need to develop new consensus criteria for 
NF2 that differentiate NF2 from schwannomatosis and remove criteria with poor specificity. 
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Table 1: Current and proposed revised (2017) Manchester Criteria for NF2  
1. Bilateral vestibular schwannomas <70+       OR 
2.   Family history AND unilateral VS             OR 
3.  Family history OR unilateral VS AND two of*: 
    meningioma, cataract, glioma, neurofibroma, schwannoma,  cerebral calcification 
(if UVS + ≥2 schwannomas only need Negative LZTR1 test)+, OR 
4.  Multiple meningioma (2 or more) AND two of: 
    unilateral VS, cataract, glioma, neurofibroma, schwannoma, cerebral calcification, OR 
5. Constitutional pathogenic NF2 gene variant in blood or identical in two tumours+ 
*Any two of includes two of any tumour type such as schwannoma 
+2017 suggested revisions (Smith et al 2017[9]) 
  
Table 2: Molecular assessment of 1361 individuals meeting NF2 diagnostic criteria or harbouring a pathogenic variant 
Category Number % of all 
NF2 
Full 
constitutional 
path_variant 
Presumed 
mosaic 
Mosaic 
blood 
Mosaic 
two 
tumours 
Two 
hits one 
tumour 
not 
seen 
blood 
Not 
found 
NF2 
pathogeni
c variant 
different 
in two 
tumours 
LZTR1 NF2 
excluded 
Proportion 
definitely 
NF2 
Proportion 
of those 
with 
definite 
diagnosis 
de novo/no affected parent   
Bilateral VS no 
FH* 680 65.7% 303 44.6% 122 84 5 33 255 
 
0 
 
0 
 
0 57.6% 100.0% 
BVS UVS first# 69 6.7% 18 26.1% 12 4 0 8 38 1 0 1 31.9% 95.7% 
UVS & 2+ 
schwannomas# 58 5.6% 5 8.5% 17 8 3 6 28 
 
1 
 
7 
 
8 27.6% 66.7% 
UVS & 2 other# 148 14.3% 18 12.2% 39 9 2 29 90 1 0 1 19.6% 96.7% 
2+ meningioma 
& 2 other 32 3.1% 13 40.6% 4 1 3 0 15 
 
0 
 
0 
 
0 53.1% 100.0% 
Pathogenic 
variant & 1 
tumour 13 1.3% 11 84.6% 2 2 0 0 0 
 
0 
 
0 
 
0 
100.0% 100.0% 
Pathogenic 
variant & 2 
tumours 8 0.8% 3 37.5% 5 0 5 0 0 
 
0 
 
0 
 
0 
100.0% 100.0% 
Schwannomatosi
s NF2 mosaic 9 0.9% 0 0.0% 9 0 9 0 0 
 
0 
 
0 
 
0 100.0% 100.0% 
UVS & sibling 
NF2 
3 0.3% 0 0.0% 0 0 0 0 0 0 0 3 0.0% 0.0% 
UVS & child NF2 2 0.2% 0 0.0% 1 1 0 0 1 0 0 0 100.0% 100.0% 
2+ Meningioma 
child NF2 
6 0.6% 0 0.0% 0 0 0 0 0 0 0 0 unknown unknown 
Ocular & 
pathogenic 
variant 
1 0.1% 1 100.0
% 
0 0 0 0 0 0 0 0 100.0% 100.0% 
Total 1029 99.4% 372 36.2% 211 109 27 76 427 3 7 13 49.4% 98.1% 
Subanalysis 
BVS only 60+ 61 5.9% 4 6.6% 
 
0 0 3 53 1 0 1 6.6% 80.0% 
Ependymoma, 
no BVS 31 3.0% 15 48.4% 8 6 0 2 8 0 0 
 
0 67.7% 100.0% 
2+ meningioma 
no BVS 137 13.2% 31 22.6% 32 17 4 11 74 0 0 
 
0 38.0% 100.0% 
parent affected 
UVS + parent 
NF2 
46 13.6% 42 91.3% 0 0 0 0 4* 0 0 0 95.7% 100.0% 
2 meningiomas 3 0.9% 3 100.0
% 
0 0 0 0 0 0 0 0 100.0% 100.0% 
2 schwannomas 40 11.8% 39 97.5% 0 0 0 0 1+ 0 0 0 100.0% 100.0% 
Bilateral VS 203 60.1% 196 96.6% 0 0 0 0 7 0 0 0 96.6% 100.0% 
Asymptomatic 
gene test 40 11.8% 40 
100.0
% 0 0 0 0 0 
0 0 0 100.0% 100.0% 
Total 332 98.2% 320 96.4% 0 0 0 0 12 0 0 0 96.4% 100.0% 
Full total 
1361  
69
2 50.8% 211 109 27 76 439 
3 7 13 60.7% 98.8% 
*7 cases presenting with bilateral VS and learning problems had ring 22; # 4 cases developed Unilateral VS + 2 additional features 22-25 years 
post childhood radiotherapy and one a contralateral VS 12 years after radiotherapy aged 17 (table 4).  
Table 3: Median age at diagnosis and Inter Quartile Range (IQR) in de novo patients in each diagnostic category by constitutional, 
mosaic/presumed mosaic and no pathogenic variant found 
 
Full constitutional path_variant Mosaic/presumed mosaic Pathogenic variant not found 
 
de novo category n median age at 
diagnosis 
IQR n median age at 
diagnosis 
IQR n median age at 
diagnosis 
IQR p value 
Bilateral VS no FH 303 21 15.0-34.0 122 31 22.0-42.25 255 48 30-62 <0.001 
BVS UVS first 18 29.5 18.5-38.5 12 32 19.25-55.25 39 48 30-61 0.003 
UVS + 2 
schwannomas 
5 13 8.0-34.0 18 36 20.75-47.0 29 41 33.5-52.0 0.016 
UVS + 2 other 18 37 23.75-60.25 39 42 32.0-49.0 91 47 36.0-58.0 0.044 
2+ meningioma + 
2 other 
13 16 8.5-20.75 4 49.5 47.25-57.75 15 35 26.0-48.0 <0.001 
Pathogenic 
variant + 1 
tumour 
11 8 4.0-15.0 2 2.5 2.0-2.5 0 
 
  0.231 
Pathogenic 
variant + 2 
tumours 
3 9 2.0-9.0 5 32 11.0-40.5 0 
 
  0.143 
Schwannomatosis 
NF2 mosaic 
0 
 
  9 44 25.0-51.5 0 
 
  n/a 
UVS + sibling NF2 0 
 
    
 
  0 
 
  
 
UVS + child NF2 0 
 
  1 50 n/a 1 44   n/a 
2+ Meningioma 
child NF2 
0 
 
  0 
 
  6 35.5 25.75-44.5 n/a 
Ocular + 
pathogenic 
variant 
0 
 
  1 1 n/a 0 
 
  n/a 
Total 371 21 15.0-34.0 213 35 23.0-47.0 435 32 32.0-60.0 <0.001 
UVS-Unilateral VS 
 Table 4: Patients meeting NF2 criteria after therapeutic radiotherapy aged <20 years 
Patient ID Age radiotherapy 
(in 5-year age 
group) 
indication sites NF2 criteria Delay to 
criteria being 
met in years  
Tumour 
analysis 
Lymphocyte 
9803462 15-19 VS Brain Bilateral VS 12 - Nil found 
937087 0-4 neuroblastoma Brain & spine Unilateral VS + 2 
spinal 
schwannoma 
25 Nil found Nil found 
157731 15-19 Lymphoreticular 
malignancy 
Brain & spine Unilateral VS + 2 
schwannoma 
22 c.1574+1G>A 
+ LOH 
Nil found 
9869906 5-9 Neurogenic 
tumour 
unrelated to NF2 
Brain Left VS, 
trigeminal 
schwannoma, 
C4 schwannoma 
22 - Nil found 
9000765 0-4 Lymphoreticular 
malignancy 
Brain & spine Unilateral VS +2 
meningiomas 
C3/4 
schwannoma 
25 - Nil found 
9116 5-9 meningioma Brain Bilateral VS 2 - c.241-9A>G  
 
